RDEB: Phase I/II—topical administration of QR‐313 (21‐nucleotide AON) in 8 patients with RDEB due to mutation(s) in exon 73 of COL7A1 (RCT). This evidence concerns the gene COL7A1 and recessive dystrophic epidermolysis bullosa.